负载HPV的PLGA微颗粒作为单剂HPV疫苗的评估:对缓释疫苗开发的启示
研究探索温度程序化负载法制备负载HPV病毒样颗粒的PLGA微颗粒,以规避有机溶剂和剪切力导致的病毒样颗粒结构功能损失,并评估其单剂缓释疫苗潜力。负载HPV的PLGA微颗粒在体内显著延长注射部位滞留并呈剂量依赖性诱导免疫原性,但单剂免疫原性低于GARDASIL®9(G9)初免/加强方案;HPV微颗粒与G9于不同部位同时接种则诱导不劣于现行标准多剂方案的抗体滴度与持久免疫应答。
要点
- 负载HPV的PLGA微颗粒经温度程序化负载制备,可减少病毒样颗粒结构功能损失。
- 负载HPV的PLGA微颗粒在体内显著延长注射部位滞留并剂量依赖性诱导免疫原性。
- 单剂HPV微颗粒免疫原性低于G9初免/加强,与G9同时不同部位接种则抗体滴度不劣于标准多剂方案。
核心结论
- 本研究成功证明开发HPV疫苗缓释制剂的可行性,并为单剂HPV疫苗的处方设计提供关于挑战与机遇的启示。
研究设计与样本
- 采用温度程序化负载法制备负载HPV病毒样颗粒的PLGA微颗粒,分离微颗粒制备与病毒样颗粒负载,并在体内评估免疫原性。
- 在兔模型中比较单剂HPV微颗粒、GARDASIL®9(G9,实验室制备的组成等效材料)初免/加强方案,以及HPV微颗粒与G9于不同注射部位同时接种的免疫应答。
主要发现
- 负载HPV的PLGA微颗粒在体内显著延长注射部位滞留并呈剂量依赖性诱导强免疫原性。
- 兔模型中单剂HPV微颗粒的免疫原性低于G9初免/加强方案,可能因处方缺乏有效佐剂。
- HPV微颗粒与G9于不同注射部位同时接种,诱导的抗体滴度不劣于现行标准多剂方案,并产生持久免疫应答。
- 作者推测G9的负荷剂量作为强效初免,而微颗粒中HPV抗原的缓释发挥加强效应。
局限性
- 单剂HPV微颗粒免疫原性低于G9初免/加强方案,可能因处方中缺乏有效佐剂。
- HPV微颗粒与G9的共配制仍具挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The human papillomavirus (HPV) vaccine is pivotal to prevent new HPV infections and associated diseases globally, which requires a multi-dose regimen to maximize protection. A long-acting HPV vaccine that can be administered in a single immunization during a doctor's visit would be highly desirable if comparable benefits are provided to that of standard of care (SoC). This work explored the development of a sustained-release HPV vaccine formulation via temperature-programmed loading of polylactic-co-glycolic acid (PLGA) microparticles (MPs). Traditional methods for fabricating HPV-loaded MPs suffer from HPV virus-like particles (VLP) structure/function loss due to exposure to organic solvents, shear stress, etc. This approach separates the microparticle fabrication from VLP loading thereby effectively minimized common stress conditions during formulation. The HPV-loaded PLGA MPs demonstrated significantly prolonged injection site retention as a depot and successfully elicited robust immunogenicity in a dose-dependent manner in vivo. However, a single dose of HPV MPs alone resulted in lower immunogenicity compared to GARDASIL®9 (G9, laboratory prepared material equivalent in composition) prime/boost in a rabbit model, likely due to the lack of an effective adjuvant in the formulation. Alternatively, concomitant administration of HPV MPs and G9 at separate injection sites was shown to induce noninferior antibody titers and durable immune response compared to the current SoC multi-dose regimen. It was hypothesized that the bolus dose of G9 served as potent prime while sustained release of HPV antigens from MPs exerted booster effect. Despite the cost benefits and convenience offered by a single injection of HPV vaccine, the co-formulation of HPV MPs with G9 remains a challenging area. In summary, this work successfully demonstrated the feasibility of developing a sustained-release formulation of HPV vaccine and provided valuable insights into challenges and opportunities of formulation design to improve efficacy, safety, and tolerability as a single-dose HPV vaccine.
引用
- Zhang Y, Sullivan N, Abraham M, et al. Evaluation of HPV-loaded PLGA microparticles as single-dose HPV vaccine: Insights for sustained-release vaccine development. Vaccine. 2025. PMID: 40139018. doi:10.1016/j.vaccine.2025.127024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。